Navigation Links
Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
Date:1/22/2008

REINACH, Switzerland, January 22 /PRNewswire-FirstCall/ -- Arpida Ltd. (SWX: ARPN) announced today that patient screening for enrolment into the pivotal Phase III study with the TLT treatment in onychomycosis has been initiated and is progressing at a very good rate.

Approximately 220 patients in total will be enrolled in this study. A substantial number of patients had already expressed their interest to participate well in advance of the trial.

The open label Phase III study will evaluate the efficacy, safety and tolerability of the TLT therapy in the treatment of patients with mild-to-moderate toenail onychomycosis. The TLT therapy consists of a one-time laser pre-treatment, followed by daily application of a topical terbinafine (the active substance of Lamisil(R)) formulation. The comparator is 8% ciclopirox lacquer (Penlac(R)) applied daily to nails that have not undergone a prior laser pre-treatment. The treatment duration will be 48 weeks in both arms.

The primary efficacy endpoint is complete cure, which is defined as 100% clear nails, negative fungal culture results and negative KOH microscopy. Arpida aims to demonstrate superiority of the TLT therapy over the comparator. Secondary endpoints include time to complete cure as well as safety and tolerability of the TLT treatment.

Dr Paul Hadvary, Head of Development of Arpida Ltd., commented: "We are very pleased with the high level of interest displayed by patients for enrolment in this study and we expect a rapid progression of the TLT treatment along its development path. The TLT therapy as a targeted approach could offer significant advantages by providing effective treatment while at the same time avoiding systemic exposure and bypassing the potential side effects of oral therapies. We are on track to complete this trial by early 2009."

About onychomycosis

Onychomycosis (OM) is a fungal infection affecting mainly toenails and, to a lesser extent fingernails
'/>"/>

SOURCE Arpida Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... (PRWEB) August 20, 2014 WriteResult®, a ... today that it has expanded its myPROpad™ ePRO tablet ... EQ-5D-5L, one of the most widely used and ... general health status. The EQ-5D is used during clinical ... a measure that can be used to demonstrate Health-Related ...
(Date:8/19/2014)... 2014 Shimadzu Scientific Instruments has ... and Nexera-i, adding to the company’s extensive line-up ... an intuitive operating environment, and full automation, the ... workflow for conventional to ultra-high-speed analysis. ... intelligent design so users can begin building the ...
(Date:8/19/2014)... 2014 Cellgen Diagnostics ... to fund a corporate lab for its genetic-based ... development is a critical component in the move ... the implementation of personalized medicine – a more ... , Indiegogo contributions will support Cellgen’s intent to ...
(Date:8/19/2014)... August 19, 2014 XenoTech announces ... and cost-effective metabolite production from bioactive small molecules. ... platform, the technology enables convenient and timely assessment ... to XenoTech’s Vice President of Commercial Operations, Christian ... assessing clinical risk can be measured directly by ...
Breaking Biology Technology:EQ-5D™ Assessment Now Available for iPad 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3
... , , ANNAPOLIS, Md., Dec. 21 ... company developing medical countermeasures against biological and chemical threats, today ... Board of Directors, increasing the Board to eight members. ... a firm providing advisory services in business risk management, homeland ...
... ... webinar, Real Time to Manufacturing Using Real-Time In Situ FTIR Analytics as a Process Analytical ... ... free webinar, Real Time to Manufacturing Using Real-Time In Situ FTIR Analytics as a ...
... ... of National Titles in 2009 Contest , ... Des Moines, Iowa (Vocus) December 18, 2009 -- DuPont congratulates Bill Wright, Walsh, ... the 2009 National Corn Growers Association (NCGA) Corn Yield Contest. Farmers planting Pioneer® brand ...
Cached Biology Technology:PharmAthene Appoints Jeffrey W. Runge, M.D. to the Company's Board of Directors 2PharmAthene Appoints Jeffrey W. Runge, M.D. to the Company's Board of Directors 3Real Time to Manufacturing Using Real-Time In Situ FTIR Analytics as a Process Analytical Technology (PAT) Tool 2DuPont Congratulates Wright for Highest Overall Yield with Pioneer Brand Hybrid 32N73 in 2009 NCGA Corn Yield Contest 2
(Date:8/20/2014)... LAKE CITY Researchers at Huntsman Cancer Institute (HCI) at ... forms of the gene that encodes BCR-ABL, the unregulated ... According to the American Cancer Society, nearly 6,000 new ... Drugs already in use, called tyrosine kinase inhibitors (TKIs), ... They do not cure CML but control it in ...
(Date:8/20/2014)... University of Tbingen, Arizona State University, the Wellcome Trust ... Institute (Swiss TPH) isolated Mycobacterium pinnipedii from ... years old. The pathogen is a relative of the ... disease in humans today. These researchers assume that seals ... "The link to sea lions was unexpected" comments Sebastien ...
(Date:8/20/2014)... SILICON VALLEY, Calif., August 19, 2014 -- Bay Area ... to diagnose and simple to cure, applauds new research ... review journal Ticks and Tick-borne Diseases . ... in Northwest California are active throughout the year, making ... conducted by researchers at California Department of Public Health ...
Breaking Biology News(10 mins):Blueprint for next generation of chronic myeloid leukemia treatment 2Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3
... A prototype drug created by researchers at the University ... of the virus responsible for severe acute respiratory syndrome, ... agents or vaccines for SARS, which killed almost 800 ... basis of their success, the researchers have received an ...
... of malaria is in prospect with a clinical drug trial ... in the trial would open the way to relief in ... fatal disease - over 500,000,000 people. , The Walter ... the Papua New Guinea Institute of Medical Research (PNGIMR) and ...
... research ?including research involving human embryonic stem cells ?is ... a position statement adopted by the Board of Directors ... the community of scientists on the front lines of ... belief that continued experimentation with human stem cells is ...
Cached Biology News:UIC developing drug for SARS 2UIC developing drug for SARS 3Old drug, new tricks: Prospects for slashing the impact of malaria 2AACR Favors 'full spectrum of stem cell research biology' 2AACR Favors 'full spectrum of stem cell research biology' 3